Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Gorog, Diana [VerfasserIn]   i
 Storey, Robert F. [VerfasserIn]   i
 Gurbel, Paul A. [VerfasserIn]   i
 Tantry, Udaya S. [VerfasserIn]   i
 Berger, Jeffrey S. [VerfasserIn]   i
 Chan, Mark Y. [VerfasserIn]   i
 Dürschmied, Daniel [VerfasserIn]   i
 Smyth, Susan S. [VerfasserIn]   i
 Parker, William A. E. [VerfasserIn]   i
 Ajjan, Ramzi A. [VerfasserIn]   i
 Vilahur, Gemma [VerfasserIn]   i
 Badimon, Lina [VerfasserIn]   i
 Berg, Jurrien M. ten [VerfasserIn]   i
 Cate, Hugo ten [VerfasserIn]   i
 Peyvandi, Flora [VerfasserIn]   i
 Wang, Taia T. [VerfasserIn]   i
 Becker, Richard C. [VerfasserIn]   i
Titel:Current and novel biomarkers of thrombotic risk in COVID-19
Titelzusatz:a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium : Consensus Statement
Verf.angabe:Diana A. Gorog, Robert F. Storey, Paul A. Gurbel, Udaya S. Tantry, Jeffrey S. Berger, Mark Y. Chan, Daniel Duerschmied, Susan S. Smyth, William A. E. Parker, Ramzi A. Ajjan, Gemma Vilahur, Lina Badimon, Jurrien M. ten Berg, Hugo ten Cate, Flora Peyvandi, Taia T. Wang and Richard C. Becker
E-Jahr:2022
Jahr:13 January 2022
Umfang:21 S.
Fussnoten:Gesehen am 21.11.2023
Titel Quelle:Enthalten in: Nature reviews. Cardiology
Ort Quelle:Basingstoke : Nature Publishing Group, 2009
Jahr Quelle:2022
Band/Heft Quelle:19(2022), 7, Seite 475-495
ISSN Quelle:1759-5010
Abstract:Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation and injury, platelet activation and hypercoagulability. Patients with COVID-19 have a prothrombotic or thrombophilic state, with elevations in the levels of several biomarkers of thrombosis, which are associated with disease severity and prognosis. Although some biomarkers of COVID-19-associated coagulopathy, including high levels of fibrinogen and d-dimer, were recognized early during the pandemic, many new biomarkers of thrombotic risk in COVID-19 have emerged. In this Consensus Statement, we delineate the thrombotic signature of COVID-19 and present the latest biomarkers and platforms to assess the risk of thrombosis in these patients, including markers of platelet activation, platelet aggregation, endothelial cell activation or injury, coagulation and fibrinolysis as well as biomarkers of the newly recognized post-vaccine thrombosis with thrombocytopenia syndrome. We then make consensus recommendations for the clinical use of these biomarkers to inform prognosis, assess disease acuity, and predict thrombotic risk and in-hospital mortality. A thorough understanding of these biomarkers might aid risk stratification and prognostication, guide interventions and provide a platform for future research.
DOI:doi:10.1038/s41569-021-00665-7
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1038/s41569-021-00665-7
 Volltext: http://www.nature.com/articles/s41569-021-00665-7
 DOI: https://doi.org/10.1038/s41569-021-00665-7
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Prognostic markers
 Thromboembolism
K10plus-PPN:1870761316
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69144809   QR-Code
zum Seitenanfang